Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marchina E van der Ende

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
The New England Journal of Medicine|August 25, 2009
Early versus deferred antiretroviral therapy for HIVLuc B Gelinck, Marchina E van der Ende
AIDS (London, England)|February 25, 2015
How does weight influence tenofovir disoproxil-fumarate induced renal function decline?Casper Rokx, Marchina E Van der Ende, Bart J A Rijnders
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 6, 2013
Peginterferon alfa-2a for AIDS-associated Kaposi sarcoma: experience with 10 patientsCasper Rokx, Marchina E van der Ende, Annelies Verbon, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 7, 2004
The effect of nevirapine on the pharmacokinetics of indinavir/ritonavir 800/100 mg BIDDavid M Burger, Jan M Prins, Marchina E van der Ende, et al.
AIDS (London, England)|April 2, 2005
Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapyJan G den Hollander, Bart J Rijnders, Gerard J J van Doornum, et al.
Virology|July 4, 2006
In vitro replication capacity of HIV-2 variants from long-term aviremic individualsHetty Blaak, Marchina E van der Ende, Patrick H M Boers, et al.
AIDS Research and Human Retroviruses|March 11, 2008
CCR5-restricted HIV type 2 variants from long-term aviremic individuals are less sensitive to inhibition by beta-chemokines than low pathogenic HIV type 1 variantsHetty Blaak, Patrick H M Boers, Marchina E van der Ende, et al.
International Journal of STD & AIDS|January 23, 2003
Post-exposure prophylaxisMarchina E van der Ende, Rosa M Regez, Gerrit Schreij, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 21, 2005
Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA studyKristel M Crommentuyn, Alwin D Huitema, Kees Brinkman, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 30, 2017
A mutation in the progesterone receptor predisposes to HEV infection in HIV-positive patientsJose D Debes, Suzan D Pas, Zwier M A Groothuismink, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
The New England Journal of Medicine|August 25, 2009
Early versus deferred antiretroviral therapy for HIVLuc B Gelinck, Marchina E van der Ende
AIDS (London, England)|February 25, 2015
How does weight influence tenofovir disoproxil-fumarate induced renal function decline?Casper Rokx, Marchina E Van der Ende, Bart J A Rijnders
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 6, 2013
Peginterferon alfa-2a for AIDS-associated Kaposi sarcoma: experience with 10 patientsCasper Rokx, Marchina E van der Ende, Annelies Verbon, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 7, 2004
The effect of nevirapine on the pharmacokinetics of indinavir/ritonavir 800/100 mg BIDDavid M Burger, Jan M Prins, Marchina E van der Ende, et al.
AIDS (London, England)|April 2, 2005
Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapyJan G den Hollander, Bart J Rijnders, Gerard J J van Doornum, et al.
Virology|July 4, 2006
In vitro replication capacity of HIV-2 variants from long-term aviremic individualsHetty Blaak, Marchina E van der Ende, Patrick H M Boers, et al.
AIDS Research and Human Retroviruses|March 11, 2008
CCR5-restricted HIV type 2 variants from long-term aviremic individuals are less sensitive to inhibition by beta-chemokines than low pathogenic HIV type 1 variantsHetty Blaak, Patrick H M Boers, Marchina E van der Ende, et al.
International Journal of STD & AIDS|January 23, 2003
Post-exposure prophylaxisMarchina E van der Ende, Rosa M Regez, Gerrit Schreij, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 21, 2005
Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA studyKristel M Crommentuyn, Alwin D Huitema, Kees Brinkman, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 30, 2017
A mutation in the progesterone receptor predisposes to HEV infection in HIV-positive patientsJose D Debes, Suzan D Pas, Zwier M A Groothuismink, et al.
Pageof 5